Raises FY25 revenue view to $4.57B-$4.62B from $4.51B-$4.58B, consensus $4.54B. Raises FY25 adjusted EBITDA view to $850M-$890M from $830M-$870M. “I am thrilled to be part of the Elanco (ELAN) team as the company is entering its next era of growth,” said Bob VanHimbergen, executive VP and CFO of Elanco Animal Health. “We are raising our 2025 full-year guidance for our strong second quarter execution and more favorable foreign exchange rates, more than offsetting incremental investments to fuel our innovation launches. I’m confident in our ability to execute on our plans, and my initial agenda is focused on driving value creation through a continuation of our productivity and cash generation efforts.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Notable companies reporting before tomorrow’s open
- Elanco announces European Commission approval of Zenrelia
- Elanco price target raised to $18 from $17 at UBS
- Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls
- Leerink upgrades Elanco following channel checks, semiannual veterinarian survey